SecBot SecBot
PRESS-RELEASE ·Filed Jul 30, 2026

MYGN

Myriad Genetics, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The magnitude of the miss and guidance cut signals worsening payer dynamics and execution challenges in Prenatal Health. Watch for further details on the Ascend restructuring and any strategic portfolio review outcomes. The stock is likely to trade down sharply; consider short-term bearish positioning until visibility improves.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.86
T+0 close · Jul 30, 2026 · via day close
Latest settled
+110.49%
T+60 · $6.02
Vs SPY
+108.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $2.86entry
  2. T+1 · 4mo ago +5.59%α +4.17% · $3.02
  3. T+5 · 3mo ago +13.99%α +10.47% · $3.26
  4. T+20 · 3mo ago +10.49%α +7.50% · $3.16
  5. T+60 · 22d ago +110.49%α +108.03% · $6.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Myriad Genetics reported Q2 2026 revenue of $190.7M (11% YoY decline, 7.4% below consensus) and adjusted EPS of -$0.25 (vs consensus -$0.06, a 317% miss). The company lowered full-year 2026 revenue guidance to $770-790M and suspended Adjusted EBITDA guidance, citing payer friction, Prenatal Health volume declines, and a $11M revenue reduction from prior-period collection estimate changes.

Key Financial Metrics

EPS
−$0.25
est −$0.06 · -316.7%
Revenue
$190.7M
est $206.0M · -7.4% · -11.0% YoY
Rating
strong miss
Guidance
$770M-$790M
lowered
Free Cash Flow
-$10.9M
Gross Margin
66.6%

Key Facts

  • Q2 2026 revenue $190.7M vs consensus $206.0M (-7.4% miss) and vs $213.1M YoY (-11%)
  • Adjusted EPS -$0.25 vs consensus -$0.06 (-316.7% miss); GAAP EPS -$0.46
  • Full-year 2026 revenue guidance lowered to $770-790M (from undisclosed prior range); Adjusted EBITDA guidance suspended
  • Prenatal Health revenue fell 16% YoY on 9% volume decline; Cancer Care Continuum revenue down 11% YoY despite 6% volume growth
  • Gross margin 66.6% vs 71.2% YoY, down 460 bps
  • Operating cash outflow $8.3M; adjusted free cash flow -$10.9M; cash $115.2M
  • Company launched Ascend initiative with professional services firm to improve efficiency and scalability

Financial Impact

Revenue miss of $15.3M vs consensus; EPS miss of $0.19; guidance cut implies ~$20-30M reduction at midpoint vs prior expectations

revenueepsgross marginguidancecash flow

Risk Factors

  • Continued payer friction and reimbursement pressure on hereditary cancer testing
  • Prenatal Health volume declines may persist
  • Cash burn ($34.5M in H1 2026) could necessitate financing if trends continue
  • Execution risk on Ascend initiative and strategic review

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
13% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3336418

Track record

16 reports on MYGN

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry price pending
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 Now $5.57 −1.76% ▲ +0.88% −0.44% vs SPY
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
  4. Nov 4, 202612d ago 8-K Mixed 6/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
  5. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 Now $5.57 −7.48% ▲ +4.49% +8.89% vs SPY
  6. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 Now $5.57 −15.99% ▲ +0.60% +0.99% vs SPY
  7. Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 Now $5.57 +0.54% ▲ +0.54% +0.02% vs SPY
  8. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 Now $5.57 +39.95% No price data
  9. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 Now $5.57 +32.62% ▼ −2.86% −2.85% vs SPY
  10. Sep 16, 20268w ago 8-K Neutral 3/10 Entry $3.86 to $4.14 Now $5.57 +44.30% ▲ +7.25% +6.12% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026